Literature DB >> 21112850

Telomere-based cancer treatment: emerging targeted therapies.

Michele Chen1, Sandra W McLeskey.   

Abstract

Chemotherapy and radiation therapy are standard care in cancer treatment; however, both have numerous adverse side effects because they affect healthy as well as cancerous cells. The side effects, including decreased white blood cell count, nausea, hair loss, and fatigue, can be severe enough that patients may decide to forgo treatment. Targeted therapies are treatments that focus on specific molecules in cancerous cells and avoid disruption of healthy cells. Telomeres, the ends of chromosomes, are possible targets. In healthy cells, telomeres become shorter with each cell division, limiting the number of divisions that a normal cell can undergo. Many cancer cells have telomerase activity, which rebuilds telomeres after each cell division and confers immortality to cancer cells. Telomerase is an enzyme normally present to a significant degree only in the cells of developing fetuses. Treatments that target the telomerase enzyme itself or the chromosomal telomeres are being developed and tested in early clinical trials. This article focuses on several approaches to telomere-targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112850     DOI: 10.1188/10.CJON.720-726

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  2 in total

Review 1.  An integrative review of factors associated with telomere length and implications for biobehavioral research.

Authors:  Angela R Starkweather; Areej A Alhaeeri; Alison Montpetit; Jenni Brumelle; Kristin Filler; Marty Montpetit; Lathika Mohanraj; Debra E Lyon; Colleen K Jackson-Cook
Journal:  Nurs Res       Date:  2014 Jan-Feb       Impact factor: 2.381

2.  Suppression of STN1 enhances the cytotoxicity of chemotherapeutic agents in cancer cells by elevating DNA damage.

Authors:  Qing Zhou; Weihang Chai
Journal:  Oncol Lett       Date:  2016-06-02       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.